Alzeimer’s Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

Alzeimer’s Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

  • December 2020 •
  • 151 pages •
  • Report ID: 5997545 •
  • Format: PDF
The global alzeimer’s drugs market grew at a CAGR of around 8% during 2014-2019.

Alzheimer’s is a disease characterized by the degeneration of nerve cells in several areas of the brain. It causes loss of cognitive function, such as memory, language, thinking and behavior. The common symptoms of Alzheimer’s include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning. It is usually diagnosed by performing physical exams, blood tests, brain imaging, and mental status and neuropsychological testing. According to the results, doctors prescribe different medications to alleviate symptoms. Alzheimer’s drugs influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.

Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer’s disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer’s drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin. The development of these drugs is anticipated to propel the market growth in the coming years. Looking forward, the analyst expects the global alzeimer’s drugs market to continue its moderate growth during the next five years.

Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global alzeimer’s drugs market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, drug class and distribution channel.

Breakup by Drug Class:
Donepezil
Galantamine
Rivastigmine
Memantine
Others

Breakup by Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Stores
Others

Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited.

Key Questions Answered in This Report:
How has the global alzeimer’s drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global alzeimer’s drugs market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global alzeimer’s drugs market and who are the key players?
What is the degree of competition in the industry?